[Guideline for management of lipid metabolism].
Ishibashi
Shun
S
Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical School.
D001629:Bezafibrate / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D012306:Risk; D019821:Simvastatin / Q000627:therapeutic use
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019821:Simvastatin; D001629:Bezafibrate